Drug intelligence / Profile preview

zanubrutinib + rituximab + lenalidomide + cyclophosphamide + doxorubicin + vincristine + prednisone

Development stage: Unknown
Lead developer: First Affiliated Hospital, Zhejiang University School of Medicine
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

ZR2 + mini-CHOP is an experimental chemo-immunotherapy regimen being investigated for the treatment of elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Developed by The First Affiliated Hospital of Zhejiang University Medical College, the regimen combines the 'ZR2' triplet—consisting of the next-generation Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib, the anti-CD20 monoclonal antibody rituximab, and the immunomodulatory agent lenalidomide—with a reduced-dose CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) backbone. This combination aims to improve efficacy in elderly populations who may not tolerate full-dose R-CHOP, by leveraging the synergistic effects of targeted therapy and immunomodulation alongside traditional cytotoxic chemotherapy.

Other names: ZR2 plus mini-CHOPZR-2 plus mini-CHOPZR 2 plus mini-CHOP

Targets

CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)CRBN (Cereblon)DNATUBB (Tubulin (alpha and beta subunits))BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on zanubrutinib + rituximab + lenalidomide + cyclophosphamide + doxorubicin + vincristine + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zanubrutinib + rituximab + lenalidomide + cyclophosphamide + doxorubicin + vincristine + prednisone.

Explore the full profile